Travere Therapeutics Inc (TVTX) Stock Price, Quote & News

Company Profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport di...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 969 7879

Website: www.travere.com

Address:

3611 Valley Centre Drive, Suite 300, San Diego, United States

Quantumup Jan. 16 at 6:23 PM

Cantor reiterated Top Pick $VERA Overweight; $100. $TVTX $NVS OTSKY $JBIO VRTX AZN $IONS RHHBY Here's what Cantor had to say: We caught up with VERA, a "Top Pick," and discussed atacicept's (APRIL/BAFF inh; BTD) potential approval in IgA nephropathy (IgAN) and commercial launch preparations... Our overall takeaway is that all the pieces are in place for a successful regulatory outcome as VERA lays the framework for a strong commercial launch.

0 · Reply

momyurich Jan. 16 at 2:57 PM

$TVTX 👍📈💸

0 · Reply

Holdyn_Baggins Jan. 15 at 9:40 PM

$TVTX look out below...

0 · Reply

Holdyn_Baggins Jan. 15 at 8:38 PM

$TVTX sellers and shorts dancing to the bottom...

0 · Reply

Holdyn_Baggins Jan. 15 at 7:28 PM

$TVTX

0 · Reply

FITTEST_RETAIL_TRADER Jan. 15 at 6:59 PM

$TVTX DR MAKARY is giving indirect reasons for why the FDA rejected TVTX’s drug.

0 · Reply

FITTEST_RETAIL_TRADER Jan. 15 at 6:55 PM

$TVTX 9900$ TVTX DRUG PRICE BEARISH SCENARIO IS INEVITABLE FDA SHOWED MERCY FOR INVESTORS

1 · Reply

rob70 Jan. 15 at 5:19 PM

$TVTX dead until April

0 · Reply

FITTEST_RETAIL_TRADER Jan. 15 at 4:44 PM

$TVTX IF THE PRICE IS GOING TO BE SAME I AM AFRAID BEARISH SCEBARIO WOULD BE INEVITABLE TVTX HAS TO DECREASE ITS PROFIT AFFORDABLE AND SUCCESFULL DRUGS ARE GOING TO BE ARPPROVED IN THIS ADMINISTRATION NOT JUST SUCCESFULL ALSO CHEAP IN THE MARKET

1 · Reply

XQuise Jan. 15 at 3:01 PM

$TVTX 🧠👈🏻🤝

0 · Reply

Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS

Jan 12, 2026, 10:55 PM EST - 4 days ago

Travere Therapeutics, Inc. (TVTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 5:00 PM EST - 4 days ago

Travere Therapeutics Provides Corporate Update and 2026 Outlook

Jan 5, 2026, 4:30 PM EST - 11 days ago

Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 11, 2025, 5:00 PM EST - 5 weeks ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2025, 6:22 PM EST - 6 weeks ago

3 Potential Mid-Cap Biotech Buyout Targets In 2026

COGT IBB XBI CYTK

Nov 26, 2025, 7:20 AM EST - 7 weeks ago

Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA

Nov 6, 2025, 11:00 AM EST - 2 months ago

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

Nov 4, 2025, 5:23 PM EST - 2 months ago

Travere Therapeutics to Participate at Upcoming Investor Conferences

Oct 31, 2025, 7:55 AM EDT - 2 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Quarter

ATEC

Oct 30, 2025, 11:26 PM EDT - 2 months ago

Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 4:01 PM EDT - 2 months ago

Travere Therapeutics Reports Third Quarter 2025 Financial Results

Oct 23, 2025, 4:30 PM EDT - 3 months ago

Travere Therapeutics to Report Third Quarter 2025 Financial Results

Oct 17, 2025, 9:01 AM EDT - 3 months ago

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

Sep 26, 2025, 7:00 AM EDT - 4 months ago

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

Sep 19, 2025, 12:53 PM EDT - 4 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB INCY MLYS SNDX

Sep 12, 2025, 3:47 PM EDT - 4 months ago

Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS

Sep 10, 2025, 2:21 PM EDT - 4 months ago

Travere: No AdCom, No Problem - Targeting Big Revenues With FSGS Approval

Sep 10, 2025, 7:01 AM EDT - 4 months ago

Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS

Sep 7, 2025, 10:09 PM EDT - 4 months ago

Travere Therapeutics, Inc. (TVTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 3:12 AM EDT - 4 months ago

Travere Therapeutics, Inc. (TVTX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 7:01 AM EDT - 4 months ago

Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism

Sep 2, 2025, 6:17 PM EDT - 4 months ago

Travere Therapeutics, Inc. (TVTX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 28, 2025, 12:40 PM EDT - 5 months ago

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari

Aug 27, 2025, 5:09 PM EDT - 5 months ago

Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI® (sparsentan) in IgA Nephropathy

Aug 12, 2025, 12:15 PM EDT - 5 months ago

Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore

Aug 6, 2025, 11:41 PM EDT - 5 months ago

Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:01 PM EDT - 5 months ago

Travere Therapeutics Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 4:30 PM EDT - 6 months ago

Travere Therapeutics to Report Second Quarter 2025 Financial Results

Jun 11, 2025, 7:01 AM EDT - 7 months ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference

Jun 10, 2025, 7:00 AM EDT - 7 months ago

Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day

Jun 4, 2025, 10:00 AM EDT - 8 months ago

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 3, 2025, 4:30 PM EDT - 8 months ago

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress

Jun 3, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation

Jun 2, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect

Jun 1, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out

May 30, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 8 months ago

Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 28, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect

May 27, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation

Quantumup Jan. 16 at 6:23 PM

0 · Reply

momyurich Jan. 16 at 2:57 PM

$TVTX 👍📈💸

0 · Reply

Holdyn_Baggins Jan. 15 at 9:40 PM

$TVTX look out below...

0 · Reply

Holdyn_Baggins Jan. 15 at 8:38 PM

$TVTX sellers and shorts dancing to the bottom...

0 · Reply

Holdyn_Baggins Jan. 15 at 7:28 PM

$TVTX

0 · Reply

FITTEST_RETAIL_TRADER Jan. 15 at 6:59 PM

$TVTX DR MAKARY is giving indirect reasons for why the FDA rejected TVTX’s drug.

0 · Reply

FITTEST_RETAIL_TRADER Jan. 15 at 6:55 PM

$TVTX 9900$ TVTX DRUG PRICE BEARISH SCENARIO IS INEVITABLE FDA SHOWED MERCY FOR INVESTORS

1 · Reply

rob70 Jan. 15 at 5:19 PM

$TVTX dead until April

0 · Reply

FITTEST_RETAIL_TRADER Jan. 15 at 4:44 PM

1 · Reply

XQuise Jan. 15 at 3:01 PM

$TVTX 🧠👈🏻🤝

0 · Reply

Holdyn_Baggins Jan. 15 at 2:56 PM

$TVTX thanks bulls! See you next pop!

0 · Reply

Holdyn_Baggins Jan. 15 at 2:39 PM

$TVTX will cover at 28 for the next pop.

0 · Reply

Holdyn_Baggins Jan. 15 at 2:27 PM

$TVTX 3,2,1…

0 · Reply

Holdyn_Baggins Jan. 15 at 12:15 PM

$TVTX

0 · Reply

Holdyn_Baggins Jan. 15 at 1:12 AM

$TVTX pajama traders dumping…

1 · Reply

Holdyn_Baggins Jan. 14 at 9:04 PM

$TVTX Ooh cannot wait for the morning dump.

0 · Reply

PatternLens_2 Jan. 14 at 8:41 PM

$TVTX Biotech mover, trend confirmation needs volume ignition and follow-through closes

1 · Reply

rob70 Jan. 14 at 7:51 PM

$TVTX ZZZZZZZZZZZzzzzzzzzzzzzzzzzz

0 · Reply

TimeForBio Jan. 14 at 7:49 PM

$TVTX It’s so dumb to short at this point. It’s obviously going to $35-40 before the PDUFA. If you think the FDA is going to reject, short at $35

1 · Reply

Holdyn_Baggins Jan. 14 at 7:19 PM

$TVTX back in for the next leg down

0 · Reply

XQuise Jan. 14 at 6:17 PM

$TVTX So many fearmongers here... seems like a good sign. Wishing everyone the happiness they deserve! 👋

2 · Reply

Crypto_chick88 Jan. 14 at 6:03 PM

$TVTX resistance at $29. might go back to $22 again

2 · Reply

Market Cap	2.54B
Revenue (ttm)	233.18M
Net Income (ttm)	-321.55M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	55.90
Profit Margin	-137.90%
Debt to Equity Ratio	0.00

Volume	2,221,300
Avg Vol	2,274,454
Day's Range	N/A - N/A
Shares Out	89.47M
Stochastic %K	34%
Beta	0.85
Analysts	Strong Sell
Price Target	$41.64